Results 231 to 240 of about 2,231,864 (278)
Some of the next articles are maybe not open access.
Current Opinion in Anaesthesiology, 2004
Risk of disease transmission and limitations in the ability to transfuse in the prehospital or combat setting have stimulated research in the field of oxygen therapeutics. Several products have completed safety trials and are presently undergoing investigation for their efficacy.
Fahim A, Habib, Stephen M, Cohn
openaire +2 more sources
Risk of disease transmission and limitations in the ability to transfuse in the prehospital or combat setting have stimulated research in the field of oxygen therapeutics. Several products have completed safety trials and are presently undergoing investigation for their efficacy.
Fahim A, Habib, Stephen M, Cohn
openaire +2 more sources
Blood Transfusion or Blood Substitution?
Vox Sanguinis, 1986Abstract. Blood transfusion has become a universally accepted, life‐saving procedure in modern clinical medicine. In addition, specific blood fractions are widely used in the therapeutic treatment of haematological disorders. Problems are, however, encountered in conventional transfusion practice and in the clinical use of blood components.
openaire +2 more sources
Transfusion Science, 1992
The problem of transmissibility of human immunodeficiency virus by blood transfusion’ and the generally increased awareness of transfusiontransmitted diseases2 have recently resulted in a resurgence of interest in artificial blood substitutes. Among these, we have to distinguish between plasma substitutes and red blood cell substitutes.
openaire +2 more sources
The problem of transmissibility of human immunodeficiency virus by blood transfusion’ and the generally increased awareness of transfusiontransmitted diseases2 have recently resulted in a resurgence of interest in artificial blood substitutes. Among these, we have to distinguish between plasma substitutes and red blood cell substitutes.
openaire +2 more sources
Perfluorocarbon blood substitutes
Critical Reviews in Oncology/Hematology, 1987The salient physicochemical properties of the fluorocarbons are briefly reviewed, including their solubility for the physiologically important gases and their properties relevant to formulation (nonmiscibility with water). The preparations used to date are described, including their properties and compositions, with some comment about the available ...
George P. Biro +2 more
openaire +2 more sources
Perfluorocarbons as blood substitutes
Annals of Emergency Medicine, 1986The development of perfluorocarbon (PFC) solutions as clinically useful oxygen-carrying agents has been a slow process because PFC is immiscible in aqueous solutions, including blood. Therefore, it has been necessary to develop emulsions for IV infusions.
openaire +2 more sources
Hemodilution and Blood Substitutes
Artificial Cells, Blood Substitutes, and Biotechnology, 1994The primary consequence of the substitution or replacement of blood with a surrogate is the dilution of the original constituents. This hemodilution produces systemic and microvascular phenomena that underlie all forms of blood replacement and provides a physiological reference for comparison for blood substitutes.
openaire +2 more sources
Critical Care Clinics, 2009
There is an ongoing need for a red cell substitute, an oxygen-carrying solution to use primarily as a bridge until red cells are available. The replacement of oxygen-carrying capacity has driven the field of research, primarily with the development of hemoglobin-based oxygen carriers, but they are less than ideal.
openaire +2 more sources
There is an ongoing need for a red cell substitute, an oxygen-carrying solution to use primarily as a bridge until red cells are available. The replacement of oxygen-carrying capacity has driven the field of research, primarily with the development of hemoglobin-based oxygen carriers, but they are less than ideal.
openaire +2 more sources
Artificial Cells, Blood Substitutes, and Biotechnology, 1998
Soluble polymerized haemoglobin (polyhaemoglobin) is now in a phase III clinical trials. Patients have received up to 20 units (10 litres) in trauma surgery and other surgery. Polyhaemoglobin can be stored for more than 1 year. Haemoglobin solutions have no blood group antigen and can be used as a 'universal donor' oxygen carrier.
openaire +2 more sources
Soluble polymerized haemoglobin (polyhaemoglobin) is now in a phase III clinical trials. Patients have received up to 20 units (10 litres) in trauma surgery and other surgery. Polyhaemoglobin can be stored for more than 1 year. Haemoglobin solutions have no blood group antigen and can be used as a 'universal donor' oxygen carrier.
openaire +2 more sources
The Search for Blood Substitutes
Scientific American, 1998M L, Nucci, A, Abuchowski
openaire +2 more sources